Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Partnering with sanofi-aventis

Partnering with sanofi-aventis

sanofi-aventis Group (Euronext:SAN; SNY) plans to increase its development activities in biologics via acquisitions and licensing deals.

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE